Semperit (SEM) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
18 Mar, 2026Executive summary
Achieved operational recovery in 2025 despite geopolitical uncertainties, tariffs, and subdued economic growth, with a clear strategy to surpass EUR 1 billion in sales through profitable growth.
Operating EBITDA reached EUR 83.6 million, above guidance, with strong margin recovery in H2 supported by cost savings and operational improvements.
Revenue declined 2.1% year-over-year to EUR 662.4 million, with EBITDA margin at 12.0% (down 0.5pp); EBIT impacted by impairments and currency effects.
Free cash flow remained solid at EUR 37.0 million, supporting a robust financial base for future investments.
Strategic focus on industrial niches, technological excellence, innovation, and high customer proximity, supported by operational discipline.
Financial highlights
Full-year revenue declined 2.1% year-on-year to EUR 662.4 million, with EBITDA down 6.4% to EUR 79.5 million (margin 12%).
Operating EBITDA at EUR 83.6 million (excluding EUR 4.1 million digitalization project costs), down 3.2% year-over-year.
EBIT at EUR 25.6 million, down 26.8% year-over-year, mainly due to impairments in LSR customer base.
Free cash flow was EUR 37.0 million, CapEx at EUR 34.7 million, and net financial debt/EBITDA at 1.2.
Earnings after tax were positive at EUR 0.4 million, significantly lower than prior year due to currency effects and impairments.
Outlook and guidance
Expects high single-digit percentage revenue growth in 2026, with both divisions contributing.
Operating EBITDA targeted at around EUR 95 million and CapEx planned at approximately EUR 50 million.
Outlook assumes moderate economic recovery and easing geopolitical uncertainty, with stronger performance in H2 2026.
Mid-term growth drivers include infrastructure programs, EU defense spending, and Ukraine reconstruction.
Latest events from Semperit
- EBITDA up 7.9% to €47.3m, medical business divested, and cost savings exceeded targets.SEM
Q2 20241 Feb 2026 - EBITDA up 11.9% to EUR 63.9m, profit positive, and 2024 guidance reaffirmed.SEM
Q3 202416 Jan 2026 - EBITDA up 21%, earnings positive, and free cash flow nearly doubled despite weak demand.SEM
Q4 202424 Dec 2025 - Q3 2025 profit turnaround and strong order intake support a confident full-year EBITDA outlook.SEM
Q3 202517 Dec 2025 - Q1 2025 saw steep profit declines, improved cash flow, and cautious optimism for H2 recovery.SEM
Q1 202526 Nov 2025 - Q2 recovery lifted order intake and margins; full-year EBITDA guidance and CapEx confirmed.SEM
Q2 202523 Nov 2025